Loading…
← CockpitCompetitor Analysis › 8086.T NIPRO CorporationOpen in the cockpit ↗

NIPRO Corporation8086.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Japanese maker of medical devices and pharmaceutical packaging, including glass vials, syringes and dialysis products.

≈ A diversified med-device/pharma-packaging maker like a smaller Becton DickinsonMomentum neutral 42
Mkt cap
$1.68B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$6.63M
20-day average traded
Fwd P/E
15.8×
forward earnings
ROIC−WACC
-2.4 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · JPY¥1,443
1D-1.7%
1W+8.4%
1M+5.5%
3M-9.5%
6M-11.0%
YTD-2.3%
1Y-3.0%
ATR %2.7%
52w lowhigh18.0% off high

What NIPRO does

Japanese maker of medical devices and pharmaceutical packaging, including glass vials, syringes and dialysis products.

Sells disposable medical products that hospitals reorder, such as syringes, needles and dialysis products, alongside glass vials and pre-filled syringes sold to drug companies, where regulatory qualification locks in orders. It also makes generic medicines.

In one line: A diversified med-device/pharma-packaging maker like a smaller Becton Dickinson.

Products and services

  • Pharmaceutical glass/plastic packaging
  • Dialysis products
  • Syringes/injection devices
  • Pharmaceutical contract manufacturing

Customers

  • Pharmaceutical companies
  • Hospitals/dialysis clinics

Where it sits in the supply chain

  • Health care
  • Medical devices and pharma packaging
  • Glass/plastic pharma packaging…

What could go right

  • Aging population dialysis demand
  • Pharma packaging outsourcing growth

What could go wrong

  • Hospital/pharma capex cyclicality

Moat: narrow (scale, regulatory licence, installed base). Broad regulated manufacturing footprint and long qualification cycles with pharma customers.

Headquarters: Osaka, Japan · Founded: 1954 · Employees: 38,593

Named competitors

NIPRO at a glance

Size NIPRO (8086.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.68B, the 539th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,443 on 18 Nov 2026.

Performance Over six months the shares fell 11.0%, against +1.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 5.0% over the last twelve months (peer median +9.4%); the operating margin is 5.4% (peer median 13.6%).

Valuation It trades at 15.8× forward earnings against a peer median of 23.8× (5th cheapest of 19).

Capital Return on invested capital runs 2.4 points below its cost of capital (5.0% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 1008086.T 90
Six months, rebased to 100: NIPRO against the median of its 20 peers (local-currency closes).

NIPRO financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥683B¥661B¥645B¥587B¥545B
Revenue growth—+2%+10%+8%—
Gross profit¥215B¥213B¥194B¥174B¥166B
EBITDA¥101B¥101B¥92.2B¥81.2B¥66.5B
Net income¥10.8B¥13.5B¥5.11B¥11.1B¥4.58B
Free cash flown/a-¥7.67B-¥8.15B-¥21.3B-¥74.7B
Capital expendituren/a¥62.3B¥76.6B¥94.3B¥85.1B
Total debt¥660B¥638B¥632B¥630B¥596B

Quarterly statements and history in the cockpit →

NIPRO competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%+20%INSPKMTSXRAYEMBLA301363LMATBFLY6699301087CHEMM7716688531POLYMEDVITRENOV68496880166960268A8086.T6-month return →1-month return →
Up and to the right = strong over both horizons. NIPRO is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×INSPXRAYEMBLA301363LMAT6699301087CHEMM7716688531POLYMEDVITRENOV684968801669608086.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NIPRO is the large dot.

NIPRO competitors and peer comparison

Head to head with its named competitors (8086.T vs BDX vs FME.DE vs 4543.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
NIPRO 8086.T$1.68B-11%+5%5%15.8×n/a
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Fresenius Medical Care FME.DE$11.2B+3%-1%11%9.5×-4.8%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%

How NIPRO compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NIPRO against its 20 peers (data as of 18 Nov 2026)
Measure8086.TPeer medianRank in peer set
1-month return+5.5%-5.2%6th highest of 21
6-month return-11.0%+1.9%7th lowest of 21
Distance from 52-week high-18.0%-26.7%6th highest of 21
Revenue growth (TTM)+5.0%+9.4%8th lowest of 21
Operating margin5.4%13.6%6th lowest of 21
Forward P/E15.8×23.8×5th cheapest of 19
ROIC minus cost of capital-2.4 pp+0.9 pp9th lowest of 21
EV / EBITDA8.5×11.2×5th cheapest of 14
Net debt / EBITDA5.3×-1.0×most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%

Questions

Who are NIPRO's main competitors?
Named competitors: Becton Dickinson (BDX), Fresenius Medical Care (FME.DE), Terumo (4543.T). The cockpit's measured peer set (industry) also includes Inspire Medical Systems (INSP), Kestra Medical Technologies (KMTS), DENTSPLY SIRONA (XRAY), Embla Medical hf (EMBLA.CO), Mehow Innovative (301363.SZ), LeMaitre Vascular (LMAT).
Is NIPRO expensive compared with its peers?
On forward p/e it trades at 15.8× against a peer median of 23.8×, 5th cheapest of 19 in its peer set.
How has NIPRO stock performed?
Over six months to 18 Nov 2026 the shares returned -11.0% against +1.9% for the median peer; over one year -3.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.